208 related articles for article (PubMed ID: 31176743)
1. DEPTOR inhibits cell proliferation and confers sensitivity to dopamine agonist in pituitary adenoma.
Yao H; Tang H; Zhang Y; Zhang QF; Liu XY; Liu YT; Gu WT; Zheng YZ; Shang HB; Wang Y; Huang JY; Wei YX; Zhang X; Zhang J; Wu ZB
Cancer Lett; 2019 Sep; 459():135-144. PubMed ID: 31176743
[TBL] [Abstract][Full Text] [Related]
2. The KBTBD6/7-DRD2 axis regulates pituitary adenoma sensitivity to dopamine agonist treatment.
Liu YT; Liu F; Cao L; Xue L; Gu WT; Zheng YZ; Tang H; Wang Y; Yao H; Zhang Y; Xie WQ; Ren BH; Xiao ZH; Nie YJ; Hu R; Wu ZB
Acta Neuropathol; 2020 Sep; 140(3):377-396. PubMed ID: 32572597
[TBL] [Abstract][Full Text] [Related]
3. The long noncoding RNA-H19/miRNA-93a/ATG7 axis regulates the sensitivity of pituitary adenomas to dopamine agonists.
Wu Z; Zheng Y; Xie W; Li Q; Zhang Y; Ren B; Cai L; Cheng Y; Tang H; Su Z; Wu ZB
Mol Cell Endocrinol; 2020 Dec; 518():111033. PubMed ID: 32946927
[TBL] [Abstract][Full Text] [Related]
4. Phosphoproteome Analysis Reveals Estrogen-ER Pathway as a Modulator of mTOR Activity Via DEPTOR.
Cuesta R; Gritsenko MA; Petyuk VA; Shukla AK; Tsai CF; Liu T; McDermott JE; Holz MK
Mol Cell Proteomics; 2019 Aug; 18(8):1607-1618. PubMed ID: 31189691
[TBL] [Abstract][Full Text] [Related]
5. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
Wang S; Wang A; Zhang Y; Zhu K; Wang X; Chen Y; Wu J
BMC Endocr Disord; 2021 Nov; 21(1):235. PubMed ID: 34814904
[TBL] [Abstract][Full Text] [Related]
6. Pituitary Tumor Suppression by Combination of Cabergoline and Chloroquine.
Lin SJ; Wu ZR; Cao L; Zhang Y; Leng ZG; Guo YH; Shang HB; Zhao WG; Zhang X; Wu ZB
J Clin Endocrinol Metab; 2017 Oct; 102(10):3692-3703. PubMed ID: 28973192
[TBL] [Abstract][Full Text] [Related]
7. Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively.
Tang C; Sun R; Wen G; Zhong C; Yang J; Zhu J; Cong Z; Luo X; Ma C
Cell Death Dis; 2019 Apr; 10(5):335. PubMed ID: 31000722
[TBL] [Abstract][Full Text] [Related]
8. Suppression of mTOR pathway and induction of autophagy-dependent cell death by cabergoline.
Lin SJ; Leng ZG; Guo YH; Cai L; Cai Y; Li N; Shang HB; Le WD; Zhao WG; Wu ZB
Oncotarget; 2015 Nov; 6(36):39329-41. PubMed ID: 26513171
[TBL] [Abstract][Full Text] [Related]
9. ACT001 reverses resistance of prolactinomas via AMPK-mediated EGR1 and mTOR pathways.
Zhu J; Tang C; Cong Z; Yuan F; Cai X; Yang J; Ma C
Endocr Relat Cancer; 2021 Dec; 29(2):33-46. PubMed ID: 34821219
[TBL] [Abstract][Full Text] [Related]
10. DEPTOR Deficiency-Mediated mTORc1 Hyperactivation in Vascular Endothelial Cells Promotes Angiogenesis.
Ding Y; Shan L; Nai W; Lin X; Zhou L; Dong X; Wu H; Xiao M; Zhou X; Wang L; Li T; Fu Y; Lin Y; Jia C; Dai M; Bai X
Cell Physiol Biochem; 2018; 46(2):520-531. PubMed ID: 29614494
[TBL] [Abstract][Full Text] [Related]
11. Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1.
Jian M; Du Q; Zhu D; Mao Z; Wang X; Feng Y; Xiao Z; Wang H; Zhu Y
J Endocrinol Invest; 2019 Jun; 42(6):639-652. PubMed ID: 30370446
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
Dai C; Zhang B; Liu X; Ma S; Yang Y; Yao Y; Feng M; Bao X; Li G; Wang J; Guo K; Ma W; Xing B; Lian W; Xiao J; Cai F; Zhang H; Wang R
Endocrinology; 2013 Mar; 154(3):1247-59. PubMed ID: 23384836
[TBL] [Abstract][Full Text] [Related]
13. Dynamic modelling of the mTOR signalling network reveals complex emergent behaviours conferred by DEPTOR.
Varusai TM; Nguyen LK
Sci Rep; 2018 Jan; 8(1):643. PubMed ID: 29330362
[TBL] [Abstract][Full Text] [Related]
14. DEPTOR is an in vivo tumor suppressor that inhibits prostate tumorigenesis via the inactivation of mTORC1/2 signals.
Chen X; Xiong X; Cui D; Yang F; Wei D; Li H; Shu J; Bi Y; Dai X; Gong L; Sun Y; Zhao Y
Oncogene; 2020 Feb; 39(7):1557-1571. PubMed ID: 31685947
[TBL] [Abstract][Full Text] [Related]
15. Dopamine agonist resistance-related endocan promotes angiogenesis and cells viability of prolactinomas.
Cai L; Leng ZG; Guo YH; Lin SJ; Wu ZR; Su ZP; Lu JL; Wei LF; Zhuge QC; Jin K; Wu ZB
Endocrine; 2016 Jun; 52(3):641-51. PubMed ID: 26662185
[TBL] [Abstract][Full Text] [Related]
16. OTUB1 protein suppresses mTOR complex 1 (mTORC1) activity by deubiquitinating the mTORC1 inhibitor DEPTOR.
Zhao L; Wang X; Yu Y; Deng L; Chen L; Peng X; Jiao C; Gao G; Tan X; Pan W; Ge X; Wang P
J Biol Chem; 2018 Mar; 293(13):4883-4892. PubMed ID: 29382726
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of mTORC1 by lncRNA H19 via disrupting 4E-BP1/Raptor interaction in pituitary tumours.
Wu ZR; Yan L; Liu YT; Cao L; Guo YH; Zhang Y; Yao H; Cai L; Shang HB; Rui WW; Yang G; Zhang XB; Tang H; Wang Y; Huang JY; Wei YX; Zhao WG; Su B; Wu ZB
Nat Commun; 2018 Nov; 9(1):4624. PubMed ID: 30397197
[TBL] [Abstract][Full Text] [Related]
18. microRNA-181a downregulates deptor for TGFβ-induced glomerular mesangial cell hypertrophy and matrix protein expression.
Maity S; Bera A; Ghosh-Choudhury N; Das F; Kasinath BS; Choudhury GG
Exp Cell Res; 2018 Mar; 364(1):5-15. PubMed ID: 29397070
[TBL] [Abstract][Full Text] [Related]
19. NEK2 regulates cellular proliferation and cabergoline sensitivity in pituitary adenomas.
Jian F; Sun Y; Sun Q; Zhang B; Bian L
J Cancer; 2021; 12(7):2083-2091. PubMed ID: 33754007
[No Abstract] [Full Text] [Related]
20. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas.
Li Z; Liu Q; Li C; Zong X; Bai J; Wu Y; Lan X; Yu G; Zhang Y
Mol Cell Endocrinol; 2015 Feb; 402():64-71. PubMed ID: 25578603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
